Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionGeneDx Holdings Corp. Class A Common Stock (WGS)
Fair value (3 models)
Not available
ACCE price target
$65.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Price used: $56.15 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
33
out of 100
Analysts
100% buy
8 covering
P/E
0.0x
forward 63.3x
1-year return
-55.1%
Dividend yield
0.00%
GeneDx Holdings Corp. Class A Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
GeneDx sells genetic sequencing and interpretation services, mainly exome and genome tests ordered for rare disease and newborn screening, and it bills payers and health systems per test. Its 69.4% gross margin says the testing workflow earns well once volume is there, but the company is still loss-making at the operating line, with a -15.2% operating margin and a -40.8% ROE. Revenue growth of 11.4% is modest for a name at a forward P/E of 63.3, so the multiple is leaning on margin expansion that has not yet shown up in the reported numbers. The score of 33/100 and the absence of any index membership reflect that gap between the story and the earnings. It merits a deeper look mainly to test whether operating leverage on the existing test volume can close a 15-point margin shortfall without a sharp slowdown in top-line growth.